Kyoto University · 20 Nov 2026 · Supplements / medicine
In mice, imeglimin lined up with less islet injury after transplant; human islets have not been tested
A 20 November 2026 research note from Kyoto University, written in Japanese, reports mouse work by Muhammad Fauzi, Takaaki Murakami, Daisuke Yabe, and colleagues. Imeglimin, a medicine already used for type 2 diabetes, limited low-oxygen injury in mouse islets and lined up with better early engraftment and glucose control after islet transplant in a mouse model of type 1 diabetes. In the islet experiments, mitochondrial function held up and reactive oxygen species rose less. A receptor-targeted scan, indium-111 exendin-4 SPECT/CT, showed more beta-cell signal at day 14. The group says that scan is a tool they hope to use in care, and the figure in the release is a diagram, not a measured image. The paper appeared online in Diabetes on 18 November 2026 and was picked as a Paper of the Month. The authors say the next check has to be human islets. This is not a study of imeglimin for a longer life, and it is not a reason to start, stop, or swap a prescribed diabetes medicine. DOI 10.2337/db26-0360. Not medical advice.
Read at Kyoto University →Our summary♡ Save
- study





